Magazine Article | November 1, 2022

Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

San Diego-based Aristea Therapeutics, spun out of AstraZeneca in 2018 and led by founder, president, and CEO James Mackay, is less than one year away from a clinical trial read-out that could change the company’s trajectory, as well as advance a new drug candidate into late-stage trials for a rare disease with no approved products on the market. With nine employees, Phase 2 trials of lead candidate RIST4721 in multiple conditions, and a uniquely assembled $123 million funding runway, Aristea awaits next year’s Phase 2b trial results in palmoplantar pustulosis (PPP), a rare inflammatory disorder.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader